Abarelix

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Abarelix
Abarelix.svg
Clinical data
Trade names Plenaxis
AHFS/Drugs.com Monograph
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration
Intramuscular injection
ATC code
Pharmacokinetic data
Protein binding 96–99%
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C72H95ClN14O14
Molar mass 1416.06 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[1][2]

It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[1] and is now marketed by Speciality European Pharma in Germany[3] after receiving a marketing authorisation in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions.[4]

References[edit]

  1. ^ a b Drugs.com: Abarelix
  2. ^ Boccon-Gibod, L.; Van Der Meulen, E.; Persson, B. -E. (2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer". Therapeutic Advances in Urology. 3 (3): 127–140. doi:10.1177/1756287211414457. PMC 3159401Freely accessible. PMID 21904569. 
  3. ^ Pharmazeutische Zeitung online: Abarelix (German)
  4. ^ Boris Minev (13 January 2011). Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Springer Science & Business Media. pp. 182–. ISBN 978-90-481-9704-0.